Join our daily newsletter At The Bell to receive exclusive market insights
- U.S.-based medical device company Imricor Medical Systems (IMR) has entered a trading halt ahead of a capital raising
- At this stage, it is unclear how much Imricor will raise and what the funds will be used for
- This week, the company secured two purchase agreements with a French hospital and a German university medical centre
- In the past six weeks alone, Imricor has contracted five sites to adopt its interventional cardiovascular magnetic resonance (iCMR)-guided catheter ablations
- Imricor last traded for $2.55 on Wednesday, October 28
Imricor Medical Systems (IMR) has entered a trading halt ahead of a capital raising.
The company will remain in a trading halt until the earlier commencement of trading on Monday, November 2, unless details of the raise are announced beforehand.
At this stage, it is unclear how much Imricor will raise and what the funds will be used for.
Imricor is a U.S.-based medical device company which develops innovative MRI-compatible devices which can be used to carry out MRI-guided procedures.
In the last three days, the healthcare stock secured two purchase agreements with European-based companies.
The first was an agreement with the Jaques Cartier Private Hospital’s Institut Cardiovasculaire Paris Sud (ICPS). ICPS is the first site in France to adopt Imricor’s technology for interventional cardiovascular magnetic resonance (iCMR)-guided catheter abltations and has already established an iCMR lab.
The second was with the Schleswig-Holstein University Medical Centre in Lübeck, Germany, which is the fifth site Imricor has contracted in the past six weeks.
“This is the organic growth we envisioned, and we are thrilled to see iCMR guided ablations gaining traction, despite COVID,” Chair and CEO Steve Wedan said.
Imricor last traded for $2.55 on Wednesday, October 28.
